(2S)-2-[(3S,8aS)-3-(4-azaniumylbutyl)-1,4-dioxo-6,7,8,8a-tetrahydro-3H-pyrrolo[1,2-a]pyrazin-2-yl]-4-phenylbutanoate

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (2S)-2-[(3S,8aS)-3-(4-azaniumylbutyl)-1,4-dioxo-6,7,8,8a-tetrahydro-3H-pyrrolo[1,2-a]pyrazin-2-yl]-4-phenylbutanoate
• 化学式: C21H29N3O4
• 分子量: 387.5
• InChiKey: FUEMHWCBWYXAOU-BZSNNMDCSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.1
• 重原子数：
  28
• 可旋转键数：
  8
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  108
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• Stereochemical investigations on the diketopiperazine derivatives of enalapril and lisinopril by NMR spectroscopy
  作者：Ádám Demeter、Tamás Fodor、János Fischer

  DOI：10.1016/s0022-2860(98)00399-8

  日期：1998.11

  Abstract Stereochemical analysis of epimeric diketopiperazine (DKP) derivatives of enalapril and lisinopril has been performed by NMR spectroscopy. The present study focuses on the configurational assignment and conformational characteristics of the epimeric DKPs obtained from cyclization and subsequent base-catalyzed hydrolysis. We report full 1 H and 13 C assignments as obtained by a concerted use

  摘要已通过核磁共振光谱对依那普利和赖诺普利的差向异构二酮哌嗪 (DKP) 衍生物进行立体化学分析。本研究的重点是通过环化和随后的碱催化水解获得的差向异构 DKP 的构型分配和构象特征。我们报告了通过协同使用 1D 和 2D 方法获得的完整 1 H 和 13 C 分配。各个立体中心的配置和主要构象特征来自测量的标量和 NOE 连接。侧链的一个显着构象特征是它倾向于在哌嗪二酮环上弯曲。
• Lisinopril formulations
  申请人：Silvergate Pharmaceuticals, Inc.

  公开号：US10039800B2

  公开（公告）日：2018-08-07

  Provided herein are stable lisinopril oral liquid formulations. Also provided herein are methods of using lisinopril oral liquid formulations for the treatment of certain diseases including hypertension, heart failure and acute myocardial infarction.

  本文提供了稳定的赖辛普利口服液制剂。本文还提供了使用赖诺普利口服液制剂治疗某些疾病（包括高血压、心力衰竭和急性心肌梗塞）的方法。
• Lisinopril compositions with an ingestible event marker
  申请人：OTSUKA PHARMACEUTICAL CO. LTD

  公开号：US11166939B2

  公开（公告）日：2021-11-09

  Provided herein are compositions for the ingestible administration of lisinopril. In some embodiments the compositions comprise lisinopril and silicon. In some embodiments, the compositions comprise lisinopril, silicon, magnesium metal, and copper (I) chloride. Also provided herein are apparatuses comprising the compositions provided herein. Also provided herein are methods for using the compositions and apparatuses provided herein.

  本文提供的是用于利辛普利的可摄取给药组合物。在某些实施方案中，组合物包括赖诺普利和硅。在某些实施方案中，组合物包括赖诺普利、硅、金属镁和氯化铜（I）。本文还提供了包含本文所提供的组合物的装置。本文还提供了使用本文提供的组合物和装置的方法。
• FIXED DOSE DRUG COMBINATION FORMULATIONS
  申请人：Sasmal Badal Kumar

  公开号：US20120045505A1

  公开（公告）日：2012-02-23

  Pharmaceutical formulations comprising multiple drugs, for treating or preventing cardiovascular disease. Embodiments are capsules containing individual drugs, or combinations of drugs, in the form of small tablets.
• LISINOPRIL FORMULATIONS
  申请人：Silvergate Pharmaceuticals, Inc.

  公开号：US20170209523A1

  公开（公告）日：2017-07-27

  Provided herein are stable lisinopril oral liquid formulations. Also provided herein are methods of using lisinopril oral liquid formulations for the treatment of certain diseases including hypertension, heart failure and acute myocardial infarction.